University of Virginia Researchers Publish New Study on Tropomyosin Proteoforms Showcasing Quantum-Si’s Next-Gen Protein Sequencer™ Platinum®
Quantum-Si (QSI) announced a new preprint publication demonstrating their Platinum single-molecule benchtop sequencer's capabilities in distinguishing proteoform-informative peptides within human tropomyosin genes. The study, led by Dr. Gloria Sheynkman at the University of Virginia School of Medicine, showcases Platinum's ability to achieve single amino acid resolution, differentiating TPM1 and TPM2 paralogous peptides and resolving phosphotyrosine modifications and TPM2 splice variants. The technology demonstrates advantages over traditional mass spectrometry techniques, particularly in detecting sequences with challenging molecular weights.
Quantum-Si (QSI) ha annunciato una nuova pubblicazione preprint che dimostra le capacità del loro sequenziatore da banco Platinum a singola molecola nel distinguere i peptidi informativi sui proteoformi all'interno dei geni della tropomiosina umana. Lo studio, condotto dalla Dr.ssa Gloria Sheynkman presso la Scuola di Medicina dell'Università della Virginia, mette in mostra la capacità di Platinum di raggiungere una risoluzione di singoli amminoacidi, differenziando i peptidi paraloghi TPM1 e TPM2 e risolvendo le modifiche di fosfotirozina e le varianti di splicing di TPM2. La tecnologia dimostra vantaggi rispetto alle tecniche tradizionali di spettrometria di massa, particolarmente nella rilevazione di sequenze con pesi molecolari impegnativi.
Quantum-Si (QSI) anunció una nueva publicación preprint que demuestra las capacidades de su secuestrador de moléculas únicas Platinum de escritorio para distinguir péptidos informativos de proteoformas dentro de los genes de tropomiosina humana. El estudio, dirigido por la Dra. Gloria Sheynkman en la Escuela de Medicina de la Universidad de Virginia, exhibe la capacidad de Platinum para lograr una resolución de un solo aminoácido, diferenciando los péptidos parálogo TPM1 y TPM2 y resolviendo modificaciones de fosfotirozina y variantes de empalme de TPM2. La tecnología demuestra ventajas sobre las técnicas tradicionales de espectrometría de masas, particularmente en la detección de secuencias con pesos moleculares desafiantes.
Quantum-Si (QSI)는 플래티넘 단일 분자 벤치톱 시퀀서의 능력을 보여주는 새로운 프리프린트 출판물을 발표했습니다. 이 출판물은 인간의 트로포미오신 유전자 내에서 단백질 형태를 나타내는 펩타이드를 구별하는 기능을 갖고 있습니다. 버지니아 대학교 의과대학의 글로리아 쉐잉크먼 박사가 이끄는 이 연구는 플래티넘이 단일 아미노산 해상도를 달성할 수 있는 능력을 선보이며, TPM1과 TPM2의 유사 펩타이드를 구별하고 인산티로신 수정 및 TPM2 스플라이스 변이를 해결합니다. 이 기술은 전통적인 질량 분석 기술에 비해 특히 도전적인 분자량의 서열을 탐지하는 데 있어 장점을 보여줍니다.
Quantum-Si (QSI) a annoncé une nouvelle publication préimprimée démontrant les capacités de son séquenceur de banc à molécules uniques Platinum à distinguer les peptides informatifs sur les protéoformes au sein des gènes de tropomyosine humaine. L'étude, dirigée par Dr. Gloria Sheynkman à l'École de Médecine de l'Université de Virginie, met en avant la capacité de Platinum à atteindre une résolution d'un acide aminé, différenciant les peptides paralogues TPM1 et TPM2 et résolvant les modifications de phosphotyrosine et les variants d'épissage de TPM2. La technologie démontre des avantages par rapport aux techniques traditionnelles de spectrométrie de masse, en particulier pour détecter des séquences avec des poids moléculaires difficiles.
Quantum-Si (QSI) hat eine neue Preprint-Veröffentlichung angekündigt, die die Fähigkeiten ihres Platinum-Einzelmolekül-Bench-Top-Sequenzierers demonstriert, proteoform-informative Peptide innerhalb menschlicher Tropomyosingenen zu unterscheiden. Die Studie, geleitet von Dr. Gloria Sheynkman an der School of Medicine der University of Virginia, zeigt die Fähigkeit von Platinum, eine Einzelaminosäure-Auflösung zu erreichen, indem sie die paralogen Peptide TPM1 und TPM2 differenziert sowie Phosphotyrosin-modifikationen und TPM2-Spleißvarianten auflöst. Die Technologie zeigt Vorteile gegenüber traditionellen Massenspektrometrie-Techniken, insbesondere bei der Erkennung von Sequenzen mit herausfordernden Molekulargewichten.
- Technology demonstrates superior capability in distinguishing peptide variants at single amino acid resolution
- Platform shows advantages over traditional mass spectrometry techniques
- Successfully validated through academic research collaboration
- None.
Insights
The publication of research demonstrating Platinum's capabilities in distinguishing protein variants represents an incremental technical validation rather than a significant market-moving development. While the technology shows promise in differentiating TPM proteoforms with single amino acid resolution, this is primarily a scientific proof-of-concept that doesn't immediately translate to commercial success or revenue generation.
The study's focus on tropomyosin variants and phosphotyrosine modifications demonstrates technical competence but lacks immediate financial implications. For investors, this represents ongoing R&D progress but doesn't significantly alter the company's near-term market position or revenue potential. The collaboration with UVA adds credibility but isn't likely to drive substantial business growth in the short term.
Published Preprint Demonstrates Platinum’s Capability to Discriminate Peptide Variants with Single Amino Acid Resolution
Titled "Protein Sequencing with Single Amino Acid Resolution Discerns Peptides that Discriminate Tropomyosin Proteoforms," the preprint describes how the Platinum sequencer differentiates TPM1 and TPM2 paralogous peptides that vary by only a single amino acid. It also explores the instrument’s ability to resolve phosphotyrosine modifications and TPM2 splice variants, underscoring the potential for NGPS to advance multi-omics research by providing insight into proteoform presence, structure, and function. (https://www.quantum-si.com/preprint-110724/)
“Our data highlight Platinum’s ability to accurately distinguish all major types of proteoform variation within the TPM gene family,” said Dr. Sheynkman. “This provides a more precise window into complex protein families, and this capability to precisely sequence and distinguish peptide variations paves the way for numerous applications in disease research and biomarker discovery.”
The study further explores Platinum’s capability to differentiate highly similar peptides that may define isoforms with distinct functions. Platinum’s single amino acid resolution enables it to detect sequences with molecular weights that challenge traditional mass spectrometry (MS) techniques, making it a complementary tool for MS and an asset for proteomics researchers focused on nuanced peptide differences.
“This collaboration with Dr. Sheynkman and her team at the University of
For more information on Quantum-Si’s technology and research applications, please visit The Protein Sequencing Company™ | Quantum-Si
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® instrument enables Next-Generation Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241107799485/en/
Investor
Doug Farrell, VP, Investor Relations
ir@quantum-si.com
Media
Katherine Atkinson, SVP, Commercial Marketing
media@quantum-si.com
Source: Quantum-Si Incorporated
FAQ
What capabilities did Quantum-Si's (QSI) Platinum sequencer demonstrate in the UVA study?
How does Quantum-Si's (QSI) Platinum technology compare to traditional mass spectrometry?
What are the potential applications of Quantum-Si's (QSI) Platinum sequencer according to the study?
